🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs
755

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 755 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Page 13 of 16

  1. Tebipenem Pivoxil Hydrobromide

    Spero Therapeutics

    Diabetes

    phase 1 small molecule completed

    1 trial

  2. The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

    NovoThirteen

    Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).

    phase 1 other active

    1 trial

  3. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  4. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of type 2 diabetes mellitus in adults and children aged 10 years and above, and heart failure and chronic kidney disease in adults patiens.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects.

    phase 1 other active

    1 trial

  5. UP421

    Sana Biotechnology

    Type1diabetes

    phase 1 mab active

    1 trial

  6. Understanding the effect of CagriSema, cagrilintide, and semaglutide on muscle health

    NovoThirteen

    Obesity, CCI, CCI

    phase 1 other active

    1 trial

  7. VCTX210A unit

    S.A.

    Diabetes Mellitus

    phase 1 other completed

    1 trial

  8. VCTX211

    S.A.

    Diabetes Mellitus

    phase 1 other terminated

    1 trial

  9. VEGF Trap-Eye

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 1 small molecule completed

    1 trial

  10. XeriSol glucagon

    Xeris Biopharma Holdings

    Type1diabetes

    phase 1 small molecule completed

    1 trial

  11. [14C]-rencofilstat 225mg

    Hepion Pharmaceuticals

    NASH With Fibrosis

    phase 1 small molecule completed

    1 trial

  12. [14C]HSK7653

    The First People's Hospital of Lianyungang

    Type II Diabetes

    phase 1 small molecule completed

    1 trial

  13. administration of UI068

    United Therapeutics Europe Ltd

    Diabetes Mellitus, Type 2

    phase 1 small molecule completed

    1 trial

  14. avoralstat

    Biocryst

    Diabetic Macular Edema (DME)

    phase 1 small molecule terminated

    1 trial

  15. hVEGF-A

    SANGAMO THERAPEUTICS, INC

    Diabetic Neuropathy

    phase 1 gene therapy completed

    1 trial

  16. intraconazole

    ENANTA PHARMACEUTICALS INC

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial

  17. pyroglutamate rongliflozin capsules

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Type 2 Diabetes

    phase 1 small molecule completed

    1 trial

  18. pyroglutamate rongliflozin capsules

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Diabetes Mellitus, Type 2

    phase 1 small molecule completed

    1 trial

  19. removal of omentum

    United Therapeutics Europe Ltd

    Diabetes Mellitus Type 2

    phase 1 other completed

    1 trial

  20. salvianolic acid A

    The First People's Hospital of Lianyungang

    Diabetes

    phase 1 small molecule active

    1 trial

  21. AD-4833 15 mg

    Takeda

    Diabetes Mellitus

    approved small molecule completed

    1 trial

  22. Aflibercept

    Regeneron UK Limited

    Diabetic Retinopathy

    approved small molecule completed

    2 trials

  23. Aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    approved small molecule completed

    2 trials

  24. Aflibercept (BAY86-5321, Eylea)

    Regeneron UK Limited

    Diabetic Macular Edema

    approved small molecule completed

    1 trial

  25. Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Diabetic Macular Edema (DME)

    approved small molecule active

    1 trial

  26. Aflibercept Injection

    Regeneron UK Limited

    Diabetic Retinopathy

    approved small molecule completed

    2 trials

  27. Alogliptin

    Takeda

    Diabetes Mellitus, Type 2

    approved small molecule completed

    6 trials

  28. Azilsartan

    Takeda

    Essential Hypertension Complicated by Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  29. Berberine

    The First People's Hospital of Lianyungang

    Diabetes Mellitus

    approved small molecule completed

    1 trial

  30. Berberine plus lifestyle intervention

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Obesity

    approved small molecule completed

    1 trial

  31. Blood Glucose Meter Systems

    Universal Integrated

    Diabetes

    approved other completed

    1 trial

  32. Breeze2 glucometer

    Hospital Authority, Hong Kong

    Diabetes

    approved other active

    1 trial

  33. COLECALCIFEROL , The Placebo product consists only of pure Ph. Eur. refined olive and it differs from Test product for the absence of active substance only: therefore, there are no reasons to suspect that the placebo product will undergo changes in its physical characteristics or degradation., Placebo

    Fondazione Telethon ETS

    obese elderly people with vitamin D deficiency

    approved small molecule active

    1 trial

  34. CSII

    The First People's Hospital of Lianyungang

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial

  35. Candesartan and Hydrochlorothiazide

    Takeda

    Obesity

    approved small molecule completed

    1 trial

  36. Capsules with microcrystalline cellulose, Colchicine Teva 0,5 mg, tabletten

    Disc Medicine

    Type 1 Diabetes

    approved small molecule active

    1 trial

  37. Commercial Hylenex® recombinant (hyaluronidase human injection)

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    approved small molecule completed

    1 trial

  38. Dapagliflozin

    AstraZeneca

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial

  39. Dapagliflozin 10 MG

    The First People's Hospital of Lianyungang

    Type 2 Diabetes Mellitus

    approved small molecule active

    1 trial

  40. ESOMEPRAZOLE, ESOMEPRAZOLE

    Fondazione Telethon ETS

    obesity

    approved small molecule active

    1 trial

  41. EXPAREL

    Pacira Ireland Limited

    Obesity

    approved small molecule completed

    1 trial

  42. Exenatide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  43. Exenatide

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    approved small molecule active

    1 trial

  44. Eylea 114.3 mg/ml solution for injection

    Bayer AG

    Neovascular age-related macular degeneration (nAMD), Diabetic macular edema (DME)

    approved small molecule active

    1 trial

  45. Fenofibrate 145 mg

    United Therapeutics Europe Ltd

    Diabetic Retinopathy

    approved small molecule completed

    1 trial

  46. Fespixon Cream

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diabetic Foot Ulcer (DFU)

    approved small molecule terminated

    1 trial

  47. Finerenone

    Chinese University of Hong Kong

    Patients With Type 2 Diabetes

    approved small molecule active

    1 trial

  48. Glucagon-like peptide-1 receptor agonist：Semaglutide

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    approved small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

755 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.